Alliance Global Partners analyst Scott Henry lowered the firm’s price target on Vivos Therapeutics (VVOS) to $6 from $8.25 and keeps a Buy rating on the shares after the company reported Q3 earnings with results that were at the lower end of expectations. Results will take time to improve given the business model shift from dentists to sleep specialists, notes the firm, which expects “flattish results” in Q4 and lowered its revenue forecast for 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VVOS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue